-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recent popular reports from Yimaike ★Preclinical research on mRNA therapy for liver fibrosis has achieved positive resultsYikemai broke the news ★Charles River cell line verification complete solution helps new drugs to smoothly promote the Sino-US double report.
Click on the picture and sign up now September 2021 2nd/MedClub News/--Poseida Therapeutics, a clinical-stage biopharmaceutical company, recently announced its autologous CAR-T product P-PSMA-101 for the treatment of metastatic castration-resistant prostate cancer.
Preliminary results of phased clinical trials
.
These data will be published at the virtual meeting of the 6th CAR-TCR Annual Summit to be held at 10:00 am on August 31, 2021, US Eastern Time, entitled "P-PSMA-101 is a High-Tscm Autologous CAR-T Targeting PSMA Producing Exceptionally Deep and Durable Responses in Castration-Resistant Metastatic Prostate Cancer"
.
P-PSMA-101 is designed to target prostate-specific membrane antigen (PSMA), which is expressed on metastatic castration-resistant prostate cancer cells
.
P-PSMA-101 is developed using Poseida's proprietary piggyBac DNA modification system, which can produce a high percentage of stem cell memory T cells (Tscm)
.
Eric Ostertag, MD, CEO of Poseida, will attend the CAR-TCR summit.
He said: “We are excited about the preliminary data from the Phase 1 trial of P-PSMA-101, which further proves the effectiveness of our CAR-T platform for solid tumors.
Sex
.
To date, except for hematological malignancies, other CAR-T therapies have not achieved much success
.
In our trials, the profound and long-lasting response has shown that CAR-T products are used on the appropriate technology platform.
Even at low doses, it is possible to have a good effect on solid tumors
.
"For more details, scan the QR code to read the full validity data: As of the deadline, the study recruited 9 mCRPC patients: Dose A Of 5 patients, each received a single treatment of 0.
25X10E6 cells/kg (average about 20M cells); 4 patients of dose B, each of them received a single treatment of 0.
75X10E6 cells/kg (average about 60M cells)
.
All patients received a lymphatic removal regimen consisting of 30mg/m2 fludarabine + 300mg/m2 cyclophosphamide
.
The patients received a lot of pretreatment, with an average of six-line treatment, and the median duration of the disease since diagnosis was 6.
4 years
.
The main findings include: 5 patients’ PSA (prostate specific antigen) levels decreased significantly, 3 patients’ PSA levels decreased by more than 50%, PSMA-PET imaging showed consistent improvement, and 1 patient showed evidence of complete tumor elimination.
Susan F.
Slovin, MD, vice chairman of academic management and trial researcher at the Memorial Sloan-Kettering Cancer Center, commented: “This innovative Poseida PSMA-oriented CAR-T cell platform is in metastasis.
Castration-resistant prostate cancer patients showed a strong anti-tumor response.
This is the first time I have seen such an impressive response from an immunotherapy product
.
The response of my patients in the trial far exceeded my expectations
.
"Safety and tolerability: P-PSMA-101 shows good safety and tolerability
.
A
previously reported case of macrophage activation syndrome (MAS) deteriorated due to patient non- adherence , only 3 cases of cells were observed Factor release syndrome (CRS) cases are all low-grade (1/2) and are well controlled through early treatment
.
As of the deadline, no cases of neurotoxicity (CRES/ICANS) have been observed
.
This is an open label, The multi-center, 3+3 dose-escalation phase 1 clinical trial study (NCT04249947) aims to evaluate the safety of P-PSMA-101 in up to 40 mCRPC adult subjects
.
The main purpose of this study is to determine P- The safety, effectiveness and maximum tolerated dose of PSMA-101
.
Recommended reading: Poseida announces that its first autologous CAR-T drug candidate P-PSMA-101 has completed the first patient administrationMedical Health broke the news, Poseida Chief Medical Officer Matthew Dr.
Spear said: "We believe that the key to the success of solid tumors is a product that contains a high proportion of ideal stem cell memory T cells (Tscm)
.
In this study, we have demonstrated that a high percentage of Tscm CAR-T products can home to the bone marrow, and in at least one case, can completely eliminate tumors
.
This bone marrow homing property may be particularly important for cancers that are prone to bone metastasis (such as prostate cancer)
.
More importantly, the good tolerability of our Tscm CAR-T product has extended to prostate cancer.
So far we have seen a controllable cytokine release syndrome, and it is not neurotoxic
.
"Summary According to the latest global cancer burden data released by the World Health Organization's International Agency for Research on Cancer (IARC) in 2020, prostate cancer is the second most common male tumor, second only to lung cancer, and its high incidence age is 65-80 years
.
And in recent years .
In the past, the incidence of prostate cancer in China has been increasing year by year, with nearly 120,000 new cases in 2020 alone
.
In addition, due to the low penetration rate of PSA screening and digital rectal examination in China, more than 50% of China Prostate cancer patients have metastasized when they are first diagnosed
.
Among them, castration-resistant prostate cancer (CRPC) is the terminal stage of the disease, and the overall survival rate is low.
The median survival time is less than two years.
The previous treatment plan cannot fully satisfy this.
The clinical needs of some patients
.
Therefore, more effective drugs for the treatment of CRPC need to be developed urgently
.
At the same time, what is the most suitable patient group for each new drug? How to determine the optimal administration time and order of administration for CRPC patients Is it possible to assess and determine the best combination of new and old drugs as soon as possible? How to overcome drug resistance and other issues are challenges faced by drug research and development
.
I
believe that with the attention of research and development personnel to prostate cancer, especially Continuous in-depth research on CRPC will develop safer and more efficient CRPC drugs
.
Reference materials: 1.
https:// phase-1-trial-of-p-psma-101-at-the-6th-annual-car-tcr-summit/Statement: The content in this article is only used to explore the frontiers of biomedicine and does not constitute any medical guidance, if any Please go to a regular hospital for treatment
.
Yimike has always been committed to original news reports such as cutting-edge technology, industry trends, and industry insights in bio-innovative drugs.
The high-end matrix users of all media reached 160,000+, of which industrial users accounted for more than 50%, and scientific research and clinical users accounted for about 30%.
More than 5% of users of investment institutions
.
In order to promote interactive exchanges in industry segments, we have established a number of professional WeChat groups, welcome to scan the QR code to add groups
.
Click on the picture and sign up now September 2021 2nd/MedClub News/--Poseida Therapeutics, a clinical-stage biopharmaceutical company, recently announced its autologous CAR-T product P-PSMA-101 for the treatment of metastatic castration-resistant prostate cancer.
Preliminary results of phased clinical trials
.
These data will be published at the virtual meeting of the 6th CAR-TCR Annual Summit to be held at 10:00 am on August 31, 2021, US Eastern Time, entitled "P-PSMA-101 is a High-Tscm Autologous CAR-T Targeting PSMA Producing Exceptionally Deep and Durable Responses in Castration-Resistant Metastatic Prostate Cancer"
.
P-PSMA-101 is designed to target prostate-specific membrane antigen (PSMA), which is expressed on metastatic castration-resistant prostate cancer cells
.
P-PSMA-101 is developed using Poseida's proprietary piggyBac DNA modification system, which can produce a high percentage of stem cell memory T cells (Tscm)
.
Eric Ostertag, MD, CEO of Poseida, will attend the CAR-TCR summit.
He said: “We are excited about the preliminary data from the Phase 1 trial of P-PSMA-101, which further proves the effectiveness of our CAR-T platform for solid tumors.
Sex
.
To date, except for hematological malignancies, other CAR-T therapies have not achieved much success
.
In our trials, the profound and long-lasting response has shown that CAR-T products are used on the appropriate technology platform.
Even at low doses, it is possible to have a good effect on solid tumors
.
"For more details, scan the QR code to read the full validity data: As of the deadline, the study recruited 9 mCRPC patients: Dose A Of 5 patients, each received a single treatment of 0.
25X10E6 cells/kg (average about 20M cells); 4 patients of dose B, each of them received a single treatment of 0.
75X10E6 cells/kg (average about 60M cells)
.
All patients received a lymphatic removal regimen consisting of 30mg/m2 fludarabine + 300mg/m2 cyclophosphamide
.
The patients received a lot of pretreatment, with an average of six-line treatment, and the median duration of the disease since diagnosis was 6.
4 years
.
The main findings include: 5 patients’ PSA (prostate specific antigen) levels decreased significantly, 3 patients’ PSA levels decreased by more than 50%, PSMA-PET imaging showed consistent improvement, and 1 patient showed evidence of complete tumor elimination.
Susan F.
Slovin, MD, vice chairman of academic management and trial researcher at the Memorial Sloan-Kettering Cancer Center, commented: “This innovative Poseida PSMA-oriented CAR-T cell platform is in metastasis.
Castration-resistant prostate cancer patients showed a strong anti-tumor response.
This is the first time I have seen such an impressive response from an immunotherapy product
.
The response of my patients in the trial far exceeded my expectations
.
"Safety and tolerability: P-PSMA-101 shows good safety and tolerability
.
A
previously reported case of macrophage activation syndrome (MAS) deteriorated due to patient non- adherence , only 3 cases of cells were observed Factor release syndrome (CRS) cases are all low-grade (1/2) and are well controlled through early treatment
.
As of the deadline, no cases of neurotoxicity (CRES/ICANS) have been observed
.
This is an open label, The multi-center, 3+3 dose-escalation phase 1 clinical trial study (NCT04249947) aims to evaluate the safety of P-PSMA-101 in up to 40 mCRPC adult subjects
.
The main purpose of this study is to determine P- The safety, effectiveness and maximum tolerated dose of PSMA-101
.
Recommended reading: Poseida announces that its first autologous CAR-T drug candidate P-PSMA-101 has completed the first patient administrationMedical Health broke the news, Poseida Chief Medical Officer Matthew Dr.
Spear said: "We believe that the key to the success of solid tumors is a product that contains a high proportion of ideal stem cell memory T cells (Tscm)
.
In this study, we have demonstrated that a high percentage of Tscm CAR-T products can home to the bone marrow, and in at least one case, can completely eliminate tumors
.
This bone marrow homing property may be particularly important for cancers that are prone to bone metastasis (such as prostate cancer)
.
More importantly, the good tolerability of our Tscm CAR-T product has extended to prostate cancer.
So far we have seen a controllable cytokine release syndrome, and it is not neurotoxic
.
"Summary According to the latest global cancer burden data released by the World Health Organization's International Agency for Research on Cancer (IARC) in 2020, prostate cancer is the second most common male tumor, second only to lung cancer, and its high incidence age is 65-80 years
.
And in recent years .
In the past, the incidence of prostate cancer in China has been increasing year by year, with nearly 120,000 new cases in 2020 alone
.
In addition, due to the low penetration rate of PSA screening and digital rectal examination in China, more than 50% of China Prostate cancer patients have metastasized when they are first diagnosed
.
Among them, castration-resistant prostate cancer (CRPC) is the terminal stage of the disease, and the overall survival rate is low.
The median survival time is less than two years.
The previous treatment plan cannot fully satisfy this.
The clinical needs of some patients
.
Therefore, more effective drugs for the treatment of CRPC need to be developed urgently
.
At the same time, what is the most suitable patient group for each new drug? How to determine the optimal administration time and order of administration for CRPC patients Is it possible to assess and determine the best combination of new and old drugs as soon as possible? How to overcome drug resistance and other issues are challenges faced by drug research and development
.
I
believe that with the attention of research and development personnel to prostate cancer, especially Continuous in-depth research on CRPC will develop safer and more efficient CRPC drugs
.
Reference materials: 1.
https:// phase-1-trial-of-p-psma-101-at-the-6th-annual-car-tcr-summit/Statement: The content in this article is only used to explore the frontiers of biomedicine and does not constitute any medical guidance, if any Please go to a regular hospital for treatment
.
Yimike has always been committed to original news reports such as cutting-edge technology, industry trends, and industry insights in bio-innovative drugs.
The high-end matrix users of all media reached 160,000+, of which industrial users accounted for more than 50%, and scientific research and clinical users accounted for about 30%.
More than 5% of users of investment institutions
.
In order to promote interactive exchanges in industry segments, we have established a number of professional WeChat groups, welcome to scan the QR code to add groups
.
